Ultime notizie per Durect (NASDAQ:DRRX) Azioni

Durect

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Durect Corp

HC Wainwright &amp; Co. analyst Ed Arce reiterates Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) with a Neutral.

News

Reiteration

Analyst Ratings

DRRX

HC Wainwright & Co. Reiterates Neutral on Durect

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. The company reported quarterly sales of $1.927 million which missed the analyst consensus estimate of $1.975 million by 2.43 percent. This is a 10.49 percent increase over sales of $1.744 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Durect Q3 2024 GAAP EPS $(0.14) Beats $(0.17) Estimate, Sales $1.927M Miss $1.975M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Durect to report an earnings per share (EPS) of $-0.17.
Anticipation surrounds Durect's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 5.67% drop in the share price the next day.
Here's a look at Durect's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.22</td>
<td>-0.33</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.25</td>
<td>-0.10</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-14.000000000000002%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731438341_0.png" alt="eps graph" />
<h3>Tracking Durect's Stock Performance</h3>
Shares of Durect were trading at $1.29 as of November 11. Over the last 52-week period, shares are up 111.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DRRX/earnings">To track all earnings releases for Durect visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Durect's Earnings

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Durect to report an earnings per share (EPS) of $-0.17.
Durect bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 5.67% drop in the share price the next day.
Here's a look at Durect's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.22</td>
<td>-0.33</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.25</td>
<td>-0.10</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>-14.000000000000002%</td>
<td>-10.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731435381_0.png" alt="eps graph" />
<h3>Performance of Durect Shares</h3>
Shares of Durect were trading at $1.29 as of November 11. Over the last 52-week period, shares are up 111.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DRRX/earnings">To track all earnings releases for Durect visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Durect

Biotech

General

DURECT Announces Phase 3 Registrational Trial Design For Larsucosterol In Alcohol-Associated Hepatitis; Type B Meeting With FDA Held Under Breakthrough Therapy Designatoin Resulted In Agreement On Aspects Of Phase 3 Design, Says Single Phase 3 Trial Designed To Enroll 200 U.S. Patients With A 90-day Survival Primary Endpoint; Topline Results Expected Within Two Years Of Trial Initiation

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 29.41 percent. The company reported quarterly sales of $2.171 million which missed the analyst consensus estimate of $2.492 million by 12.87 percent. This is a 4.32 percent increase over sales of $2.081 million the same period last year.

Durect Q2 2024 GAAP EPS $(0.12) Beats $(0.17) Estimate, Sales $2.171M Miss $2.492M Estimate

<h3>Gainers</h3>
<ul>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares moved upwards by 7.39% to $14.66. The market value of their outstanding shares is at $879.1 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares rose 7.35% to $2.92. The company's market cap stands at $46.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares decreased by 13.2% to $1.12 during Tuesday's after-market session. The market value of their outstanding shares is at $34.7 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares decreased by 10.1% to $0.75. The company's market cap stands at $4.5 million. </li>
<li>Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) shares decreased by 8.79% to $85.0. The market value of their outstanding shares is at $4.3 billion. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) stock fell 7.36% to $6.93. The market value of their outstanding shares is at $2.6 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 7.27% to $2.17. The company's market cap stands at $9.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 6.16% to $0.24. The market value of their outstanding shares is at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDRX

CING

IMNM

LFST

MBIO

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

NUWE

RZLT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rumors

Watching DURECT; Traders Circulate Unconfirmed Analyst Comments Suggesting A $5 PT on The Stock After FDA Feedback

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. </li>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock rose 23.07% to $1.28. The market value of their outstanding shares is at $39.7 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) stock rose 17.33% to $8.53. The market value of their outstanding shares is at $544.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 16.64% to $0.91. The market value of their outstanding shares is at $149.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares rose 14.81% to $3.72. The company's market cap stands at $72.9 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Citius Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 14.62% to $0.76. The market value of their outstanding shares is at $136.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock decreased by 21.9% to $0.12 during Tuesday's pre-market session. The market value of their outstanding shares is at $8.2 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) stock decreased by 16.31% to $0.46. The company's market cap stands at $15.8 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock decreased by 15.68% to $0.1. The company's market cap stands at $11.6 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock fell 15.28% to $0.23. The market value of their outstanding shares is at $6.1 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares decreased by 13.77% to $0.15. The company's market cap stands at $5.6 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock declined by 12.12% to $0.12. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

Envoy Medical, Inc. - Class A Common Stock

COCH

CTXR

KZIA

Larimar Therapeutics, Inc. - Common Stock

LRMR

ORGS

SCPX

SINT

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Health Care

DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis

WIIM

DURECT shares are trading lower after the company reported a year-over-year decrease in Q1 revenue results.

DURECT Q1 2024 EPS $(0.25) Up From $(0.52) YoY; Revenue $1.8M Down From $2.1M YoY

Oppenheimer analyst Francois Brisebois reiterates Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) with a Outperform and maintains $5 price target.

Price Target

Oppenheimer Reiterates Outperform on Durect, Maintains $5 Price Target

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported its Q4 earnings results on Wednesday, March 27, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Durect beat estimated earnings by 70.0%, reporting an EPS of $-0.1 versus an estimate of $-0.33.
Revenue was down $646 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.28 which was followed by a 3.0% increase in the share price the next day.
Here's a look at Durect's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.42</td>
<td>-0.51</td>
<td>-0.53</td>
<td>-0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.14</td>
<td>-0.46</td>
<td>-0.52</td>
<td>-0.46</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.97M</td>
<td>2.94M</td>
<td>2.89M</td>
<td>3.48M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.74M</td>
<td>2.08M</td>
<td>2.05M</td>
<td>3.31M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Durect <a href="https://www.benzinga.com/quote/DRRX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Durect: Q4 Earnings Insights

Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.33) by 69.7 percent. The company reported quarterly sales of $2.669 million which beat the analyst consensus estimate of $2.477 million by 7.77 percent. This is a 19.49 percent decrease over sales of $3.315 million the same period last year.

Durect Q4 2023 GAAP EPS $(0.10) Beats $(0.33) Estimate, Sales $2.669M Beat $2.477M Estimate

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company's shares closed yesterday at $1.22. ...

Durect (DRRX) Receives a Hold from H.C. Wainwright

Durect ( ($DRRX) ) has shared an announcement. At DURECT Corporation's 2024 Annual Meeting, stockholders authorized expanding the 2000 Stock Plan t...

Durect Corp Annual Meeting Decisions and Shareholder Votes

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aytu BioScience (AYTU – Research Report), Inventiva ...

Analysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)

DURECT Q3 2024 Earnings Preview

Here are the major earnings after the close today

DURECT GAAP EPS of -$0.14 beats by $0.03, revenue of $1.92M misses by $0.06M

Reports Q3 revenue $1.9M, consensus $1.97M. "We remain focused on preparations for the Phase 3 trial for larsucosterol in severe alcohol-associated...

Durect reports Q3 EPS (14c), consensus (17c)

DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript

DURECT Corporation ( ($DRRX) ) has released its Q3 earnings. Here is a breakdown of the information DURECT Corporation presented to its investors. ...

DURECT Corporation's Q3 2024 Financial Highlights

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Durect (DRRX – Research Report), with a price target o...

Northland Securities Sticks to Its Buy Rating for Durect (DRRX)

AOIFF

BDORY

NLCP

PVCT

SMSI

SONO

SPRU

TLPH

TTEK

VXRT

Press Releases

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

Durect

Notizie

Ultime notizie per Durect (NASDAQ:DRRX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO